DDInter1442 DDInter1676
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Phenobarbital {u} (Compound) resembles {v} (Compound) Primidone
Phenobarbital {u} (Compound) resembles {v} (Compound) Methsuximide
Phenobarbital {u} (Compound) treats {v} (Disease) epilepsy syndrome
Phenobarbital {u} (Compound) binds {v} (Gene) ABCC3
Phenobarbital {u} (Compound) causes {v} (Side Effect) Mental disability
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Sunitinib
Phenobarbital (Compound) resembles Primidone (Compound)
Phenobarbital (Compound) resembles Methsuximide (Compound)
Phenobarbital (Compound) treats epilepsy syndrome (Disease)
Phenobarbital (Compound) binds ABCC3 (Gene)
Phenobarbital (Compound) causes Mental disability (Side Effect)
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Phenobarbital may lead to a major life threatening interaction when taken with Sunitinib